The pharma's Sandoz division will be handing commercialization of reSET, reSET-O and future therapies back to Pear over the course of a transition period.
Get and save the most relevant links from around the web. Tailored for you.
Or continue with Twitter, Facebook, Google
Already a member? Sign in